Skip to content

Ketamine research published in 2022

Page 13 of 14: studies 241 to 260 of 261, newest first. Back to the ketamine overview

Studies

A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis.

Psychiatry Research 2022 Qiuwen Li, Sai-Ying Wang, Xi Mei

The feasibility of intravenous ketamine administration during the perioperative period of cesarean section to prevent postpartum depression (PPD) has not been determined by meta-analysis. To evaluate the efficacy, safety and dose of prophylactic ketamine in offsetting PPD, we retrieved the following databases in English or Chinese from inception to December 2020: Pubmed, Embase, Web of Science,...

The Myths of Uncontrolled Emergence Reactions and Consideration to Stop Mandatory, Protocolled Midazolam Coadministration With Ketamine.

Journal of special operations medicine : a peer reviewed journal for SOF medical professionals 2022 Hugh M Hiller, Brendon Drew, Andrew D Fisher et al.

Ketamine continues to demonstrate its utility and safety in the austere and prehospital environment, but myths persist regarding the frequency of behavioral disturbances and unpleasant reactions. These myths have led to protocolled midazolam co-administration. Properties of midazolam and other benzodiazepines have the potential to cause significant morbidity and potential mortality. Because of...

Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review.

Frontiers in Pain Research 2022 Aksharra Balachandran, Vanessa K Tassone, Fathima Adamsahib et al.

Pain and depression frequently co-occur. Due to its antidepressant and analgesic properties, ketamine has been used for the management of treatment-resistant depression and pain. This systematic review examined the literature on the efficacy of sub-anesthetic doses of ketamine in individuals experiencing comorbid depression and chronic pain (CDCP), as well as comorbid depression and acute pain...

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.

Journal of Affective Disorders 2022 Lynnette A. Averill, Christopher L. Averill, Ralitza Gueorguieva et al.

Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine. Here we...

Distinct downstream targets of the medial prefrontal cortex underlie discrete antidepressant responses to ketamine

Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022 Ryota Shinohara, Brendan Hare, Rong-Jian Liu et al.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the prototype for a potential new generation of glutamate-based antidepressants that rapidly relieve symptoms of depression within hours of treatment. Studies in rodents have demonstrated that neuroplasticity in the medial prefrontal cortex (mPFC) is critical for the antidepressant actions of ketamine. However, effector circuits...

DOI: 10.1254/jpssuppl.95.0_1-o-011 (opens in new tab) Ketamine Prefrontal cortex Stria terminalis Antidepressant +4

What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide?

Frontiers in Psychiatry 2022 Mark A Gillman

Medication dosages are crucial-no single dose fits all. My paper compares the safety, scientific and practical applicability of fixed 25-50% concentrations of nitrous oxide (N2O) with the variable titrated concentrations of Psychotropic Analgesic N2O (PAN), as used in dentistry, and neuropsychiatry. A crucial difference is that PAN is always titrated, via an open circuit (nasal mask), to the...

Capacity for consciousness under ketamine anaesthesia is selectively associated with activity in posteromedial cortex in rats

Neuroscience of Consciousness 2022 A. Arena, Bjørn E. Juel, R. Comolatti et al.

Abstract It remains unclear how specific cortical regions contribute to the brain’s overall capacity for consciousness. Clarifying this could help distinguish between theories of consciousness. Here, we investigate the association between markers of regionally specific (de)activation and the brain’s overall capacity for consciousness. We recorded electroencephalographic responses to cortical...

Corrigendum: A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression.

Frontiers in Psychiatry 2022 Shannon Dames, Pamela Kryskow, Crosbie Watler correction

Corrigendum: A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers with PTSD and DepressionError in Figure/TableIn the published article, there was an error in Figure 2 as published. The PTSD label on the legend that is imbedded in the figure was on the legend component of the figure was posted on the anxiety...

Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder.

Frontiers in Psychiatry 2022 Joshua Willms, Ben McCauley, Lindsay Kerr et al.

Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...

DOI: 10.3389/fpsyt.2022.1020214 (opens in new tab) Full text (opens in new tab) Depression Ketamine assisted psychotherapy Medical school Suicidality

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Journal of Affective Disorders 2022 L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al. 60 citations

BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...

Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.

Biochemical and Biophysical Research Communications 2022 Ya-Ting Wang, Ning-Ning Zhang, Ling Liu et al. 47 citations

PURPOSE OF REVIEW To explore the convergent downstream pathways of ketamine and rapastinel and drive further development of identification for following generational rapid-acting antidepressants in the synaptic process. RECENT FINDINGS Ketamine is an NMDAR antagonist and is proven effective in depression for the rapid and sustained antidepressant response, while rapastinel is an NMDAR positive...

Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.

Journal of Neurological Sciences 2022 Subha Subramanian, S. Haroutounian, Ben J Palanca et al. 58 citations

Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...

Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression.

Psychopharmacology 2022 Edem Ekpenyong Edem, Collins-Kevin Chukwudi Anyanwu, Kate Eberechukwu Nebo et al. 9 citations

Major depressive disorder (MDD) is a serious mental disorder with influence across the functional systems of the body. The pathogenesis of MDD has been known to involve the alteration of normal body functions responsible for the normal inflammation processes within the CNS; this along with other effects results in the depreciation of the sensorimotor performance of the body. Ketamine...

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.

Psychiatry Research 2022 Joshua D. Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues et al. 11 citations

Antidepressants are associated with symptomatic worsening in a subgroup of patients. Replicated evidence has demonstrated rapid and robust antidepressant effects with intravenous (IV) ketamine in treatment resistant depression (TRD); however, the risk of ketamine worsening depressive symptoms in a subgroup of patients remains unknown. Herein we report a retrospective analysis on the rates of...

Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats.

Neurobiology of Stress 2022 Zhuoyu Ren, Mingling Wang, Mokhtar Aldhabi et al. 28 citations

Rapid antidepressant effects of S-ketamine have repeatedly been confirmed in patients with depression, as well as in chronic unpredictable mild stress (CUMS) animal models. However, the pharmacological study of S-ketamine for anti-postpartum depression has not been considered. In this study, the classical method of reproductive hormone withdrawal was used to construct a rat model of postpartum...

Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.

Frontiers in Psychiatry 2022 Ryan Yip, Jennifer Swainson, Atul Khullar et al. 13 citations

Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this...

DOI: 10.3389/fpsyt.2022.1017504 (opens in new tab) Full text (opens in new tab) Hypertension Hypertensive emergency Ketamine infusion Treatment resistant depression

Antidepressant Effect of Ketamine on Inflammation‐Mediated Cytokine Dysregulation in Adults with Treatment‐Resistant Depression: Rapid Systematic Review

Oxidative Medicine and Cellular Longevity 2022 Shiryn D. Sukhram, Grozdena Yilmaz, Jianying Gu 26 citations

Background . Major depressive disorder (MDD) and treatment‐resistant depression (TRD) represent a global source of societal and health burden. To advise proper management of inflammation‐related depression among TRD patients, it is important to identify therapeutic clinical treatments. A key factor is related to proinflammatory cytokines such as interleukin‐ (IL‐) 1 β , IL‐6, and tumor necrosis...

Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats.

British Journal of Pharmacology 2022 Kristýna Štefková-mazochová, Hynek Danda, Wim Dehaen et al. 13 citations

Deschloroketamine (DCK), a structural analogue of ketamine, has recently emerged on the illicit drug market as a recreational drug with a modestly long duration of action. Despite it being widely used by recreational users, no systematic research on its effects has been performed to date. Pharmacokinetics, acute effects, and addictive potential in a series of behavioural tests in Wistar rats...

DOI: 10.1111/bph.15680 (opens in new tab) Full text (opens in new tab) Nmda receptor Deschloroketamine Enantiomers Locomotion +2

Making the Case for Psychedelics: Comparing Alternative Treatment Options for Depression

2022 Nicole Amavisca, Nicole Amavisca 1 citation

Given the number of people who are treated for depression each year and the knowledge that treatments work differently for everyone, there is a pressing need to provide a variety of treatment options. Although psychedelic research had been halted for a few decades due to recreational abuse, there has been revived interest due to its therapeutic potential in the treatment of mood disorders and...

Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.

Frontiers in Psychiatry 2022 Udo Bonnet, Michael Specka, Ann-Kristin Kanti et al. 4 citations

There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts. We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of...